Arifa Khan


Dr. Arifa S. Khan is Head, Molecular Retrovirology Unit, Division of Viral Products, OVRR/CBER/U.S. FDA. She moved her retrovirus program from NIAD/NIH to CBER in 1991 where she is currently leading high-throughput sequencing efforts to address endogenous retrovirus and adventitious virus safety concerns in biologics. Her primary regulatory responsibilities include candidate viral vaccines, including SARS-COV-2. She provides expert consultation to other CBER Offices and CDER. Dr. Khan has been involved in licensure of several viral vaccines and development of FDA, ICH, PHS, USP, and WHO documents. Dr. Khan obtained her Ph.D. in Microbiology from the George Washington University, Washington, D.C. She has authored more than 100 publications.